glp-1 allodynia Helpful tips from my followers and should you stop GLP-1's if you start to experience as a side effect? #glp1community #obesitymedicine #doctorsofinstagram Allodynia and semaglutide: complete guide

In recent years, the FDA has begun approving GLP-1s specifically for chronic weight management to help treat obesity, as they can increase satiety, decrease hunger and result in significant weight loss

doi:10.1056/NEJMoa2505669

Eligibility Requirements When BCBS plans do cover Wegovy, coverage is generally based on meeting the following criteria: Obesity (BMI of 30 or higher) Overweight (BMI of 27 or higher) with at least one weight-related medical condition, such as hypertension, high cholesterol, or type 2 diabetes Coverage may also be available for other FDA-approved indications, including cardiovascular risk reduction and MASH treatment

The patients who discontinued GLP-1 medication also sustained improvements in glycemic control, with hemoglobin A1c levels remaining below the threshold for diabetes

Table 4 lists the agents currently available in the USA and their dosing strategies [19, 38, 55,56,57,58]

Navarro DJ, Alpert PT, Cross C (2019) The impact of shift work on diabetes self-management activities